Drug General Information
Drug ID	D0C3CF
Former ID	DIB003479
Drug Name	SDZ-NVI-085
Drug Type	Small molecular drug
Indication	Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32]		Discontinued in Phase 1	[544963]
Company	Novartis AG
Structure		Download 2D MOL 3D MOL
Formula	C15H21NO2S
Canonical SMILES	c12c(C[C@@H]3[C@@H](C1)OCCN3C)c(ccc2SC)OC
CAS Number	CAS 104195-17-7
PubChem Compound ID	128503
Target and Pathway
Target(s)	Alpha-1A adrenergic receptor	Target Info	Antagonist	[534234]
KEGG Pathway	Calcium signaling pathway
	cGMP-PKG signaling pathway
	Neuroactive ligand-receptor interaction
	AMPK signaling pathway
	Adrenergic signaling in cardiomyocytes
	Vascular smooth muscle contraction
	Salivary secretion
PANTHER Pathway	Alpha adrenergic receptor signaling pathway
Reactome	Adrenoceptors
	G alpha (q) signalling events
	G alpha (12/13) signalling events
WikiPathways	Monoamine GPCRs
	Calcium Regulation in the Cardiac Cell
	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Endothelin Pathways
	GPCR ligand binding
	GPCR downstream signaling
	AMPK Signaling
References
Ref 544963	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001726)
Ref 534234	SDZ NVI 085, an alpha 1A-adrenoceptor agonist with 5-HT2A receptor antagonist properties. Eur J Pharmacol. 1996 Feb 15;297(1-2):83-6.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.